Tolerating increases in the serum creatinine following aggressive treatment of chronic kidney disease, hypertension and proteinuria: Pre-renal success

American Journal of Nephrology

Volumn 36, Issue 5, 2012, Pages 430-437

  Hirsch, Sheldon ^a,c   Hirsch, Jackie ^a   Bhatt, Udayan ^b   Rovin, Brad H ^b  

^a Lakeside Nephrology Renal   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c NONE   (United States)

Author keywords

Angiotensin receptor blockers; CKD renin angiotensin inhibitors; CKD, aggressive treatment; Creatinine renin angiotensin inhibition; Renin angiotensin system inhibitor; Retrospective study

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; MINERALOCORTICOID ANTAGONIST; POTASSIUM; PROTEIN; SPIRONOLACTONE;

ADULT; AFRICAN AMERICAN; AGED; ALLERGIC REACTION; ARTICLE; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; DIABETIC PATIENT; DISEASE COURSE; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; KIDNEY FAILURE; MALE; MEDICAL RECORD REVIEW; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; RETROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 84868260849     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000343453     Document Type: Article

References (25)

1. Bakris G, Weir M: Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine. Arch Intern Med 2000; 160:685-693.
2. Palmer B: Renal dysfunction complicating the treatment of hypertension. N Engl J Med 2002; 347: 1256-1261.
3. Holtkamp, F, de Zeeuw D, Thomas M, Cooper M, de Graeff P, Hillege H, et al: An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int 2011; 80:282-287.
4. Maschio G, Alberti D, Janin G, Locatelli F, et al: Effect of the angiotensin-converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angioten-sin-Converting Enyzme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996; 334: 939-945.
5. Klahr S, Levey A, Beck G, Caggiiula A, et al: The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N Engl J Med 1994; 330:877-884.
6. Apperloo A, DeZeeuw D, De Jong P: A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function. Kidney Int 1997; 51: 793-797.
7. National Kidney Foundation (K/DOQI): Clinical practice guideline on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43(suppl 1):S183-S218.
8. Sarnak M, Greene T, Wang X, Beck G, et al: The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the Modification of Diet in Renal Disease Study. Ann Intern Med. 2005; 142:342-351.
9. Jafar T, Stark P, Schmid C, Landa M, et al for the AIPRD Study Group: Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angioten-sin-converting enzyme inhibition. A patient-level meta-analysis. Ann Intern Med 2003; 139: 244-252.
10. Appel L, Wright J, Greene T, Agodoa L, Astor B, Bakris G, et al: Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med 2010; 363:918-929.
11. Eijkelkamp W, Zhang Z, Remuzzi G, Parving H, Cooper M, Keane W, et al: Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the reduction of endpoints in NID-DM with the angiotension II antagonist losartan (RENAAL) trial. J Am Soc Nephrol 2007; 18: 1540-1546.
12. Schieppati A, Remuzzi G: The future of reno-protection: frustration and promises. Kidney Int 2003; 64: 1947-1955.
13. Zandi-Nejad K, Brenner B: Strategies to retard the progression of chronic kidney disease. Med Clin N Am 2005; 89: 489-509.
14. Navis G, Kramer A, de Jong P: High-dose ACE inhibition: can it improve renoprotec-tion? Am J Kidney Dis 2002; 40: 664-666.
15. Schmieder R, Klingbeil A, Fleischman E, Veelken R, Delles C: Additional antiprotein-uric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study. J Am Soc Nephrol 2005; 16: 3038-3045.
16. Chrysostomou A, Pedagogoa E, MacGregor L, Becker G: Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin 2 receptor blocker. Clin J Am Soc Nephrol 2006; 1:256-262.
17. Bakris G, Weir M, Secic M, Campbell B, Weis-McNulty A: Differential effects of calciumant a goni stsub classes on markers of ne-phropathy progression. Kidney Int 2004; 65: 1991-2002.
18. Ruggenenti P, Perticucci E, Cravedi P, Gambara V, Costantini M, Sharma S, et al: Role of remission clinics in the longitudinal treatment of CKD. J Am Soc Nephrol 2008; 19: 1213-1224.
19. Hou, F, Xie, D, Zhang X, Chen P, Zhang W, Liang M, Guo Z, Jiang J: Renoprotection of Optimal Antiproteinuric Doses (ROAD) study: a randomized controlled study of bena-zepril and losartan in chronic renal insufficiency. J Am Soc Nephrol 2007; 18:1889-1898.
20. Brenner B, Dworkin L, Ichikawa I: Glomeru-lar filtration; in Brenner BM, Rector FC (eds): The Kidney, ed 3, chapt 4. Philadelphia, Saunders, 1986, pp 127-130.
21. Hirsch S: Prerenal success in chronic kidney disease. Am J Med 2007; 754-759.
22. Levey AS, Greene T, Kusek JW, et al: A simplified equation to predict glomerular filtration rate from serum creatinine (abstract). J Am Soc Nephrol 2000; 11:155A.
23. Mann J, Schmeider RE, McQueen M, et al: Renal outcomes with telmisartan, ramapril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomized, double-blind, controlled trial. Lancet 2008; 372: 547-553.
24. Tylicki L, Rutkowski P, Renke M, et al: Triple pharmacologic blockade of the renin-angio-tensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial. Am J Kidney Dis 2008; 52: 486-493.
25. Lewis J: Blood pressure control in chronic kidney disease: is less really more? J Am Soc Nephrol 2010; 21:1086-1092.